| 000 | 01635nam a22003255u 4500 | ||
|---|---|---|---|
| 001 | 283425 | ||
| 003 | SZ-BaSKA | ||
| 005 | 20241117211837.0 | ||
| 006 | m o d | ||
| 007 | cr unu | ||
| 008 | 230821s2023 sz a o 001 0 eng d | ||
| 020 | _a9783318072303 | ||
| 035 | _a(OCoLC)1391693624 | ||
| 040 |
_aUKSKG _beng _cUKSKG |
||
| 100 | 1 | _aEyre, Toby A. | |
| 245 | 1 | 0 |
_aFast Facts: Chronic Lymphocytic Leukemia / _c Toby A. Eyre, Parag Jasani, Lindsey E. Roeker _h[electronic resource] |
| 250 | _a2nd edition. | ||
| 264 |
_aBasel : _bS. Karger, _c2023 |
||
| 300 |
_a1 online resource (80 pages) : _b 8 figures, 8 in color, 8 tables |
||
| 520 | _aChronic lymphocytic leukemia (CLL) is the most diagnosed leukemia in the Western world, accounting for approximately 25% of all new leukemia diagnoses. In recent years, remarkable progress has been made in our understanding of both the pathophysiology and genetics of CLL. While the disease generally affects older adults and initially follows an indolent course, cytogenetic and molecular profiling have helped to predict clinical outcomes. Greater prognostication, alongside the development of an increasing armamentarium of novel targeted therapies, has enabled us to provide more personalized management options for patients. | ||
| 588 | 0 | _aPrint version record | |
| 650 | 1 | 4 | _aOncology |
| 650 | 1 | 4 | _aHematology |
| 700 | 1 | _aJasani, Parag | |
| 700 | 1 | _aRoeker, Lindsey E. | |
| 776 | 0 | 8 |
_iPrint version: _tFast Facts: Chronic Lymphocytic Leukemia _z9783318071603 |
| 856 |
_u#gotoholding _yAccess with NHS OpenAthens |
||
| 942 | _cEBOOK | ||
| 997 | _aHEEOUPNHS | ||
| 999 |
_c87285 _d87285 |
||